<p>Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.</p>

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

Can we harness our immune system to fight NSCLC?

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Share Can we harness our immune system to fight NSCLC?

Sign up to save your podcasts

Can we harness our immune system to fight NSCLC?

Can we harness our immune system to fight NSCLC?

More shows like GRACEcast Radiation Oncology Video

GRACEcast Head and Neck Cancer Audio

GRACEcast Lung Cancer Video

GRACEcast Radiation Oncology Audio

GRACEcast Pancreatic Cancer Audio

GRACEcast Pancreatic Cancer Video

GRACEcast Cancer 101 Audio

GRACEcast Bladder Cancer Video

GRACEcast Head and Neck Cancer Video NEW

GRACEcast Cancer 101 Video